Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Value AnalystHold
Overall Rating3.3/10
Generated at:2026-06-03 17:40:48
Analysis based on 5 financial reports covering periods: 2026-03-31, 2025-12-31, 2025-09-30, 2025-06-30, 2025-03-31. Data includes company basic information, financial condition assessment, profitability analysis, and valuation analysis. Stock price data as of June 3, 2026. Analysis considers both quantitative metrics and qualitative factors including pipeline potential and market expectations.
Overview

Moderna, Inc. is a biotechnology company focused on mRNA medicines and vaccines, currently in a challenging transitional phase post-COVID-19 vaccine revenue peak. The company shows strong liquidity but faces severe profitability pressures with significant net losses and negative cash flows. Valuation is driven by future pipeline potential rather than current financial fundamentals, making it a high-risk, high-potential-reward investment.

Valuation
2/10
Profitability
2/10
Financial health
6/10
Operation Advice
  • Current shareholders should hold and monitor pipeline progress closely.
  • New investors should wait for a more attractive entry point or clearer positive catalysts from clinical trials.
  • Based on current fundamentals, a reasonable trading range would be lower than the current price, potentially in the $30-$45 range.

Valuation

P/E TTM
-7.55
P/E LYR
-5.14
P/B MRQ
2.46
P/S TTM
--
AI Analysis
  • Valuation analysis indicates the stock appears overvalued based on traditional metrics, with a high Price-to-Sales ratio of 8.75 and negative P/E ratios. The current price of $49.06 is not supported by profitability metrics and is driven entirely by future pipeline potential expectations.
  • Current stock price is $49.06 as of June 3, 2026
  • Price-to-Sales (PS-TTM) ratio is 8.75, indicating a significant premium relative to recent sales
  • Price-to-Book (PB) ratio is 2.46, suggesting market values assets at more than twice their accounting value
  • Both forward-looking and TTM P/E ratios are negative (-5.14 and -7.55), rendering the metric meaningless as company is unprofitable
  • Given negative earnings, high PS ratio, and negative ROE, current stock price is not supported by traditional fundamental profitability metrics
  • Valuation is entirely driven by future pipeline potential rather than current financials
  • Based on current financials, the stock appears overvalued
  • Establishing precise target price using discounted cash flow is impractical due to negative and unpredictable near-term cash flows
  • A re-rating towards more conservative PB multiple of 1.5x would suggest fundamental price target closer to tangible asset support level
  • Reasonable trading range based on current fundamentals would be lower than current price, potentially $30-$45 range
Valuation trend

Profitability

ROE TTM
-36.33%
Net margin
-345.24%
Gross margin
-145.50%
Total revenue
389.00M
AI Analysis
  • Profitability analysis reveals severe challenges with significant net losses, negative gross margins, and negative return metrics. The company is experiencing profitability pressures as it transitions beyond COVID-19 revenue, with massive costs offsetting revenue growth.
  • For Q1 2026, Moderna reported net loss of $1.34 billion on revenues of $389 million
  • Gross margin was -145.50%, indicating cost of revenue vastly exceeded sales
  • Comparing year-over-year for Q1, revenue grew 260% (from $108M to $389M)
  • Profitability deteriorated sharply with net loss widening by 38% YoY
  • Gross profit swung from positive $18M to negative $566M YoY
  • Trailing twelve-month Return on Equity (ROE) is -36.33%
  • Trailing twelve-month Return on Assets (ROA) is -25.35%
  • These figures confirm company is currently destroying shareholder value
  • Company is inefficient in generating profits from its asset base
  • Moderna is experiencing severe profitability pressures
  • Surge in Q1 2026 revenue was completely offset by massive costs
  • Company is in period of investment and transition as it moves beyond COVID-19 windfall
  • Extensive R&D for pipeline is heavily weighing on current earnings
Profitability
2025Q12025Q22025Q32025Q42026Q1
ROE TTM---17.69%-19.73%-28.87%-36.33%
Earnings
2025Q12025Q22025Q32025Q42026Q1
Total revenue108.00M250.00M1.27B1.94B389.00M

Financial health

Debt/Asset
35.52%
Current ratio
2.41
Quick ratio
2.35
Cash ratio
2.35
AI Analysis
  • Financial condition assessment shows mixed signals with strong liquidity metrics but concerns about sustainability given negative profitability. The company maintains moderate leverage and sufficient short-term liquidity, but sustained losses will gradually erode cash reserves.
  • Company maintains strong short-term liquidity position
  • Current ratio of 2.41 indicates sufficient current assets to cover current liabilities
  • Quick ratio of 2.35 provides buffer for operations
  • Debt-to-asset ratio is 35.52%, suggesting moderate level of financial leverage
  • This is not excessively high for growth-stage biotech company
  • Indicates balance between using debt and equity financing
  • Company is currently reporting significant net losses and negative cash flow from operations
  • Sustaining these losses will gradually erode company's cash reserves and shareholder equity if not reversed
Leverage
2025Q12025Q22025Q32025Q42026Q1
Debt/Asset20.77%21.74%23.11%29.89%35.52%
Liquidity
2025Q12025Q22025Q32025Q42026Q1
Current ratio4.223.933.923.292.41